The rationale behind the use of PARPi in PCa can be found in the fact that, among others, a somatic/germline homologous recombination repair (HRR) gene mutation (mainly in BRCA2) plays an important role in development and progression of the disease (5). The gene discussed is BRCA2; the disease is posterior cortical atrophy.